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Recently, Winblad and colleagues
(Lundkvist et al., 2014) reported an inter-
esting point of view highlighting the
current failures of the pharmaceutical
industry to find an effective drug solu-
tion against Alzheimer’s disease, and the
difficulties rising from greater Research
and Development costs in the context
of growing regulatory and administra-
tive straitjacket. This paradigm shift may
result to a critical situation of decline
of Alzheimer’s research and therapy.
Alzheimer’s disease is a worldwide big
concern because of its expanding preva-
lence and incidence, and its numerous
adverse consequences including loss of
autonomy, poor quality of life, high
morbid-mortality and institutionalization
(Prince et al., 2013). No curative treat-
ment has been discovered so far, and the
only treatment options are symptomatic
(Anand et al., 2014). Thus, in order to
reduce Alzheimer’s impact and costs, the
development of curative drugs proves
necessary.
One solution emphasized by Winblad
and colleagues to avoid this crisis is the
back to basics way, meaning turning to
non-profit academic research to break the
deadlock (Lundkvist et al., 2014). The
value of academic research is based on
the small size of research teams, avoid-
ing too much inertia and making it pos-
sible to work through close interaction
rather than contracting; on the oppor-
tunity to test candidate molecules; and
also on their ability to work on rare dis-
eases and orphans drugs in the CNS area
that may provide indirect solutions to the
problem of Alzheimer’s disease (Lundkvist
et al., 2014). Eventually, most impor-
tantly, these biomedical academic research
teams have the opportunity to develop
more easily translational research and to
conduct action-research, a way of think-
ing together and combining research and
clinical practice (Beauchet et al., 2012).
The academic approach is indeed still
promising. Nevertheless, it is worth point-
ing out that research as conceived hitherto
could not answer a number of impor-
tant issues, leaving the door open for the
pharmaceutical industry. It is therefore
highly suitable to make academic research
evolve. The main problem was the exces-
sive fragmentation, dispersion and con-
finement of skills and knowledge fiercely
guarded by every academic research team.
Research should overcome these difficul-
ties and open up to others. Future of
research will undoubtedly be based on the
pooling of resources, research, databases,
and teams. This is exactly the purpose of
Biomathics consortium.
Biomathics is an emerging scien-
tific research consortium applied to
human systems modeling intended to
help physicians and scientists worldwide
to work together and think faster and
wider. Firmly focused on the fields of
human longevity, autonomy and predic-
tion of health issues and their adverse
consequences, Biomathics Consortium
aims at generating initiatives, linking data
from research and data from quantified-
self, i.e., the self-measure of health and
function using digital technologies to
promote health in the general popu-
lation (den Braber, 2013). Biomathics
involves researchers worldwide, operates
international collaborations, intercon-
nects research databases on health and
well-being, and initiates and/or joins
international research programs.
Biomathics connects academic research
teams working in the same research fields,
and offer them to share their respective
basis in order to compound a larger and
more comprehensive data basis. Of course,
this organization process requires to evalu-
ate similar or close outcomes, and to adopt
a shared language. Nevertheless, methods
based on effect size or z-score can combine
slightly different variables. This allows
extremely fast answers to research ques-
tions with only little additional financial
resources and using very large population-
based samples. Moreover, it is also likely
that some endpoints identified in a spe-
cific study may be of concern to another
team, or at least may respond to queries of
this second team. In such case, the request-
ing team launches an initiative within
Biomathics and contacts all teams likely to
help. Willing researchers are included in
the initiative, participate in the research,
revise the collaborative publication and
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are included in the list of co-authors
based on their involvement in the work
and the number of participants made
available.
The main strengths of Biomathics
Consortium are to make a formal link
between worldwide leading research teams
on aging and longevity, specifically those
who have not worked together thus far.
It allows building an effective worldwide
operational network, applying to grants
as a research network, training students
and fellows, and offering immediate reac-
tivity and high efficiency. It offers data
extracted from various international clin-
ical researches. It makes also possible to
screen for potential participants for future
research programs. Last, but not least, it
promotes the emergence of new ideas and
the validation of pilot projects through
international multicentric studies. For
this reason, Biomathics Consortium
is a typical and distinctive model of
“bottom-up” operation in the context
of “top-down” reorganization of most
research programs due to budgetary con-
straints and restrictions. While research
studies are increasingly built to meet
government programs and grants (“top-
down” model), Biomathics Consortium
is raised by researchers for themselves
and is intended to explore research ques-
tions that do not necessarily receive the
attention of governing bodies. In con-
vergence with top-down organization,
rapid production of big results would
eventually influence the decision-making
and change health and research poli-
cies, hence the “bottom-up” word
acceptation.
In conclusion, we are at a crucial
time for research. Times are changing,
research too. Tomorrow’s opportunities
imply global convergence, efficient net-
works, and merging academic legitimacy
and flexibility with private funds and
stringency to keep producing innova-
tive science not restricted by commer-
cial objectives. Biomathics Consortium
is intended to unify forces in order to
improve the efficiency of research and
quickly find effective treatment options for
patients. Since this is still, and always must
be, researchers’ first priority.
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